PRESCRIBED BIOLOGIC IN CRSwNP
BY ENTs AND ALLERGISTS3
THE ONLY BIOLOGIC FDA-
APPROVED
FOR PATIENTS
AGED 12-17 YEARS
with inadequately controlled CRSwNP1
WITH DUPIXENT, AIM TO BREAK THE
CYCLE OF
RECURRENCE IN CRSwNP1,2:
Sources of type 2 inflammation
- DUPIXENT targets IL‑4 and IL‑13 signaling, two of the key and central drivers of type 2 inflammation and its disease burdens1,5,6,*
*The mechanism of dupilumab action has
not been definitively established.1
- Addressing sources of type 2 inflammation may help break the cycle of recurrence—a systemic cycle of chronic symptoms, systemic steroid bursts, and sinus surgeries—in CRSwNP7-13
SYMPTOMS
- Rapid results at Day 3 for Loss of Smellb and Day 2 for nasal congestion14,c
Post hoc analysis. Results are descriptive. Definitive conclusions cannot be made.14,15
- Sustained results through
Week 521,2,d-g
Data in adults.1,2,14
CONTROL
- 83% fewer patients required surgery1
- 74% fewer patients required systemic steroids1
76% fewer patients required surgery and/or systemic steroids.1,h Individually, these were not multiplicity-adjusted endpoints.1,2 Data in adults.1
Phase 3 Clinical Trials in Adults: Coprimary Endpoints, LSM difference, DUPIXENT 300 mg Q2W + INCS vs placebo + INCS at Week 241,2
SINUS-24 (DUPIXENT n=143, placebo n=133): NC score: -0.89 (95% CI: -1.07, -0.71). NPS: -2.06 (95% CI: -2.43, -1.69).
SINUS-52 (DUPIXENT n=295, placebo n=153): NC score: -0.87 (95% CI: -1.03, -0.71). NPS: -1.80 (95% CI: -2.10, -1.51).
bLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.12, -0.02).14,16 Patient-reported outcome.14,15
cLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.13, -0.01).14,16
dLoS score at Week 24 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -0.98 (95% CI: -1.15, -0.81) (P<0.0001).2
eNC score at Week 24 in SINUS-52 (coprimary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -0.87 (95% CI: -1.03, -0.71) (P<0.0001).1,2
fLoS score at Week 52 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -1.10 (95% CI: -1.31, -0.89).1 Analysis was not multiplicity controlled. Results are descriptive.2
gNC score at Week 52 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -0.98 (95% CI: -1.17, -0.79) (P<0.0001).1
hIn SINUS-24 and SINUS-52, DUPIXENT (Day 0: n=438; Week 24: n=376; Week 52: n=100); placebo (Day 0: n=286; Week 24: n=187; Week 52: n=61).1
Loss of Smell (LoS) score (range 0-3): reduced score indicates improvement.1
Nasal congestion/obstruction (NC) score (range 0-3): reduced score indicates improvement.1
Nasal polyp score (NPS) (range 0-4 for each nostril, range 0-8 in total): reduced score indicates improvement.1
AD, atopic dermatitis; BP, bullous pemphigoid; COPD, chronic obstructive pulmonary disease; CSU, chronic spontaneous urticaria; EoE, eosinophilic esophagitis;
INCS, intranasal corticosteroids; LSM, least squares mean; PN, prurigo nodularis; Q2W, once every 2 weeks.
Use of DUPIXENT for the CRSwNP indication in patients aged 12-17 years is supported by evidence from studies of DUPIXENT as add-on maintenance treatment in adults with inadequately controlled CRSwNP.1
Multiple Administration Options
Offer your adult and pediatric patients 12 years and
older flexible administration: at home or in office.1
Demonstrated
Safety Profile1
Most common adverse reactions (incidence ≥1%) in adult patients with CRSwNP are injection site reactions,i eosinophilia,
insomnia, toothache, gastritis, arthralgia, and conjunctivitis.j
iInjection site reactions cluster includes injection site reaction, pain, bruising, and swelling.
jConjunctivitis cluster includes conjunctivitis, allergic conjunctivitis, bacterial conjunctivitis, viral conjunctivitis, giant papillary conjunctivitis, eye irritation, and eye inflammation.
View safety dataSAFETY PROFILE STUDIED IN >9000 PATIENTS ACROSS US APPROVED INDICATIONS1,17,k
Support can make all the difference for patients. DUPIXENT MyWay is a patient support program that can get them started on DUPIXENT with coverage support, financial assistance for eligible patients, one-on-one nursing support, and more.
Check Formulary Status in
Your Area
See the coverage status for DUPIXENT, prior authorization, and
step edit information by ZIP code.
Contact a Field Representative
Connect with a DUPIXENT Field Representative to get answers to
your product-related questions.